US3984396A
(en)
*
|
1971-06-01 |
1976-10-05 |
Icn Pharmaceuticals, Inc. |
1-(β,-D-ribofuranosyl)-1,2,4-triazole acid esters
|
DE2401449A1
(de)
*
|
1973-01-16 |
1974-07-25 |
Voorhees |
Pharmazeutische zusammensetzung zur linderung von hautproliferationserkrankungen
|
US3888843A
(en)
*
|
1973-06-12 |
1975-06-10 |
Toyo Jozo Kk |
4-carbamoyl-1-' -d-ribofuranosylimidazolium-5-olate
|
AR207138A1
(es)
*
|
1974-03-18 |
1976-09-15 |
Icn Pharmaceuticals |
Metodo para la obtencion de 1,2,4-triazoles n-substituidos y sus sales de adicion
|
GB1482736A
(en)
*
|
1974-03-18 |
1977-08-10 |
Icn Pharmaceuticals |
1-(beta-d-ribofuranosyl)-1,2,4-triazole acid derivatives
|
US3960836A
(en)
*
|
1974-07-22 |
1976-06-01 |
Eli Lilly And Company |
Acylated derivatives of pyrazofurin and process for their preparation
|
US4007198A
(en)
*
|
1975-05-01 |
1977-02-08 |
American Cyanamid Company |
Substituted 1,2,4-triazole carboxamide
|
US4138547A
(en)
*
|
1977-12-22 |
1979-02-06 |
Icn Pharmaceuticals, Inc. |
Process for preparing 1,2,4-triazole nucleosides
|
JPS57146593A
(en)
*
|
1981-03-09 |
1982-09-10 |
Ajinomoto Co Inc |
Preparation of ribofuranosyltriazole derivative
|
US4451648A
(en)
*
|
1981-08-19 |
1984-05-29 |
The United States Of America As Represented By The Department Of Health And Human Services |
Process for the production of 2-β-D-ribofuranosylthiazole-4-carboxamide
|
US4531001A
(en)
*
|
1982-03-23 |
1985-07-23 |
Brigham Young University |
2-β-D-ribofuranosylselenazole-4-carboxamide compounds
|
US4446315A
(en)
*
|
1982-09-24 |
1984-05-01 |
The United States Of America As Represented By The Department Of Health And Human Services |
Adenosine 5'-triphosphate-4-carboxamide-ribofuranosylthiazole
|
JPS5964648U
(ja)
*
|
1982-10-22 |
1984-04-28 |
阿波野 政晴 |
日覆用骨格
|
BE902199A
(fr)
*
|
1984-10-29 |
1985-07-31 |
Vira Tek Inc |
Procede de traitement medical de maladies virales utilisant le 1-beta-d-ribofurannosyl-1, 2,4-triazole-3-carboxamide.
|
NZ213370A
(en)
*
|
1985-01-16 |
1989-03-29 |
Vira Tek Inc |
Method of treating viral infections of selected trees and field crops using ribavirin (1-b-d-ribofuranosyl-1,2,4-triazole-3-carboxamide) or the 2,3,5-triacetyl or 5'-butyryl derivative thereof
|
DE3606634A1
(de)
*
|
1986-02-28 |
1987-09-03 |
Mack Chem Pharm |
Isohexid-nucleoside, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
|
DE3650505T2
(de)
*
|
1986-03-27 |
1996-09-19 |
Gensia Inc |
AICA riboside zur prophylaktischen Behandlung von Krankheiten mit einer verminderten Durchblutung.
|
US4925930A
(en)
*
|
1988-11-02 |
1990-05-15 |
Nucleic Acid Research Institute |
Synthesis and anti-leukemic activity of alkyl-1-(β-D-ribofuranosyl)[1,2,4]triazole-3-carboximidates
|
US5438131A
(en)
*
|
1992-09-16 |
1995-08-01 |
Bergstrom; Donald E. |
3-nitropyrrole nucleoside
|
YU47802A
(sh)
*
|
1999-12-23 |
2006-03-03 |
Ribapharm |
Postupci i kompozicije za levovirin
|
US6455508B1
(en)
*
|
2000-02-15 |
2002-09-24 |
Kanda S. Ramasamy |
Methods for treating diseases with tirazole and pyrrolo-pyrimidine ribofuranosyl nucleosides
|
US6495677B1
(en)
*
|
2000-02-15 |
2002-12-17 |
Kanda S. Ramasamy |
Nucleoside compounds
|
US7638496B2
(en)
*
|
2000-02-15 |
2009-12-29 |
Valeant Pharmaceuticals North America |
Nucleoside analogs with carboxamidine modified monocyclic base
|
MY164523A
(en)
*
|
2000-05-23 |
2017-12-29 |
Univ Degli Studi Cagliari |
Methods and compositions for treating hepatitis c virus
|
JP5230052B2
(ja)
*
|
2000-05-26 |
2013-07-10 |
イデニクス(ケイマン)リミテツド |
フラビウイルスおよびペスチウイルス治療のための方法および組成物
|
US6815542B2
(en)
*
|
2000-06-16 |
2004-11-09 |
Ribapharm, Inc. |
Nucleoside compounds and uses thereof
|
MXPA03001528A
(es)
*
|
2000-08-22 |
2004-04-02 |
Ribapahrm Inc |
Especificidad mejorada en el tratamiento de enfermedades.
|
US6878364B2
(en)
*
|
2000-12-01 |
2005-04-12 |
Cornell Research Foundation, Inc. |
Animal model for flaviviridae infection
|
US20040014696A1
(en)
*
|
2000-12-07 |
2004-01-22 |
Johnson Lau |
Specificity in treatment of diseases
|
US6720000B2
(en)
*
|
2001-03-19 |
2004-04-13 |
Three Rivers Pharmaceutical, Llc |
Process for producing wet ribavirin pellets
|
EP1281715B1
(en)
*
|
2001-07-30 |
2003-10-22 |
Clariant Life Science Molecules (Italia) SpA |
Process for the preparation of ribavirin
|
JP2005504087A
(ja)
*
|
2001-09-28 |
2005-02-10 |
イデニクス(ケイマン)リミテツド |
4’が修飾されたヌクレオシドを使用するc型肝炎ウイルス治療のための方法および組成物
|
CA2465159A1
(en)
*
|
2001-11-02 |
2003-05-15 |
Sandoz Inc. |
Process for preparing quick dissolving, high loading ribavirin compositions
|
KR100411398B1
(ko)
|
2001-12-06 |
2003-12-18 |
주식회사유한양행 |
베타-디-리보푸라노즈 유도체의 제조방법
|
CN103275159A
(zh)
|
2002-06-28 |
2013-09-04 |
埃迪尼克斯医药公司 |
用于治疗黄病毒感染的修饰的2’和3’-核苷前药
|
WO2004002422A2
(en)
|
2002-06-28 |
2004-01-08 |
Idenix (Cayman) Limited |
2’-c-methyl-3’-o-l-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections
|
US7608600B2
(en)
*
|
2002-06-28 |
2009-10-27 |
Idenix Pharmaceuticals, Inc. |
Modified 2′ and 3′-nucleoside prodrugs for treating Flaviviridae infections
|
NZ537662A
(en)
*
|
2002-06-28 |
2007-10-26 |
Idenix Cayman Ltd |
2'-C-methyl-3'-O-L-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections
|
US20040067877A1
(en)
*
|
2002-08-01 |
2004-04-08 |
Schinazi Raymond F. |
2', 3'-Dideoxynucleoside analogues for the treatment or prevention of Flaviviridae infections
|
US7538094B2
(en)
*
|
2002-09-19 |
2009-05-26 |
Three Rivers Pharmacueticals, Llc |
Composition containing ribavirin and use thereof
|
SI1576138T1
(sl)
|
2002-11-15 |
2017-07-31 |
Idenix Pharmaceuticals Llc |
2'-metil nukleozidi v kombinaciji z interferon in flaviviridae mutacijo
|
AU2003300901A1
(en)
*
|
2002-12-12 |
2004-06-30 |
Idenix (Cayman) Limited |
Process for the production of 2'-branched nucleosides
|
BR0316868A
(pt)
*
|
2002-12-23 |
2005-10-25 |
Idenix Cayman Ltd |
Processo para a produção de pró-medicamentos de nucleosìdeo-3'
|
RU2005133093A
(ru)
*
|
2003-03-28 |
2006-07-27 |
Фармассет, Инк. (Us) |
Соединения для лечения флавивирусных инфекций
|
EP2345657A1
(en)
*
|
2003-05-30 |
2011-07-20 |
Pharmasset, Inc. |
Modified fluorinated nucleoside analogues
|
EP1658302B1
(en)
*
|
2003-07-25 |
2010-08-25 |
IDENIX Pharmaceuticals, Inc. |
Purine nucleoside analogues for treating diseases caused by flaviviridae including hepatitis c
|
WO2005018330A1
(en)
*
|
2003-08-18 |
2005-03-03 |
Pharmasset, Inc. |
Dosing regimen for flaviviridae therapy
|
US20050187192A1
(en)
*
|
2004-02-20 |
2005-08-25 |
Kucera Pharmaceutical Company |
Phospholipids for the treatment of infection by togaviruses, herpes viruses and coronaviruses
|
EP1912643A2
(en)
*
|
2004-06-23 |
2008-04-23 |
Idenix (Cayman) Limited |
5-aza-7-deazapurine derivatives for treating infections with flaviviridae
|
CN101023094B
(zh)
*
|
2004-07-21 |
2011-05-18 |
法莫赛特股份有限公司 |
烷基取代的2-脱氧-2-氟代-d-呋喃核糖基嘧啶和嘌呤及其衍生物的制备
|
PL3109244T3
(pl)
*
|
2004-09-14 |
2019-09-30 |
Gilead Pharmasset Llc |
Wytwarzanie 2'fluoro-2'-alkilo-podstawionych lub innych ewentualnie podstawionych rybofuranozylopirymidyn i puryn oraz ich pochodnych
|
EP2305695A3
(en)
|
2005-07-25 |
2011-07-27 |
Intermune, Inc. |
Macrocyclic inhibitors of Hepatitis C virus replication
|
MX2008004754A
(es)
*
|
2005-10-11 |
2009-03-02 |
Intermune Inc |
Compuestos y metodos para inhibir la replicacion viral de hepatitis c.
|
CA2634749C
(en)
*
|
2005-12-23 |
2014-08-19 |
Idenix Pharmaceuticals, Inc. |
Process for preparing a synthetic intermediate for preparation of branched nucleosides
|
CA2643680A1
(en)
|
2006-04-11 |
2007-11-22 |
Novartis Ag |
Hcv/hiv inhibitors and their uses
|
US7964580B2
(en)
|
2007-03-30 |
2011-06-21 |
Pharmasset, Inc. |
Nucleoside phosphoramidate prodrugs
|
WO2009028575A1
(ja)
|
2007-08-27 |
2009-03-05 |
National University Corporation Nagoya University |
血液凝固第vii因子プロモーターの活性化剤及びその利用
|
JPWO2009028573A1
(ja)
|
2007-08-27 |
2010-12-09 |
国立大学法人名古屋大学 |
血液凝固障害におけるリバビリンの利用
|
US20090082414A1
(en)
*
|
2007-09-26 |
2009-03-26 |
Protia, Llc |
Deuterium-enriched viramidine
|
WO2009105258A1
(en)
|
2008-02-22 |
2009-08-27 |
Nektar Therapeutics Al, Corporation |
Oligomer conjugates of heteropentacyclic nucleosides
|
TW200946541A
(en)
*
|
2008-03-27 |
2009-11-16 |
Idenix Pharmaceuticals Inc |
Solid forms of an anti-HIV phosphoindole compound
|
US8048862B2
(en)
*
|
2008-04-15 |
2011-11-01 |
Intermune, Inc. |
Macrocyclic inhibitors of hepatitis C virus replication
|
US8173621B2
(en)
*
|
2008-06-11 |
2012-05-08 |
Gilead Pharmasset Llc |
Nucleoside cyclicphosphates
|
WO2010045266A1
(en)
*
|
2008-10-15 |
2010-04-22 |
Intermune, Inc. |
Therapeutic antiviral peptides
|
CN102272134B
(zh)
|
2008-12-09 |
2013-10-16 |
吉里德科学公司 |
Toll样受体调节剂
|
WO2010075554A1
(en)
|
2008-12-23 |
2010-07-01 |
Pharmasset, Inc. |
Synthesis of purine nucleosides
|
PA8855601A1
(es)
*
|
2008-12-23 |
2010-07-27 |
|
Forformidatos de nucleósidos
|
CN102753563A
(zh)
*
|
2008-12-23 |
2012-10-24 |
吉利德制药有限责任公司 |
核苷类似物
|
US20110182850A1
(en)
|
2009-04-10 |
2011-07-28 |
Trixi Brandl |
Organic compounds and their uses
|
US8512690B2
(en)
|
2009-04-10 |
2013-08-20 |
Novartis Ag |
Derivatised proline containing peptide compounds as protease inhibitors
|
US8618076B2
(en)
|
2009-05-20 |
2013-12-31 |
Gilead Pharmasset Llc |
Nucleoside phosphoramidates
|
TWI598358B
(zh)
|
2009-05-20 |
2017-09-11 |
基利法瑪席特有限責任公司 |
核苷磷醯胺
|
AU2010298028A1
(en)
*
|
2009-09-28 |
2012-04-19 |
Intermune, Inc. |
Cyclic peptide inhibitors of hepatitis C virus replication
|
US20110082182A1
(en)
*
|
2009-10-01 |
2011-04-07 |
Intermune, Inc. |
Therapeutic antiviral peptides
|
WO2011076923A1
(en)
|
2009-12-23 |
2011-06-30 |
Institut National De La Sante Et De La Recherche Medicale |
Inhibitor for inosine monophosphate (imp) dehydrogenase and/or viral rna polymerase for treatment of hepatitis e
|
US8933110B2
(en)
|
2010-01-25 |
2015-01-13 |
Enanta Pharmaceuticals, Inc. |
Hepatitis C virus inhibitors
|
MA34013B1
(fr)
*
|
2010-01-25 |
2013-02-01 |
Enanta Pharm Inc |
Inhibiteurs du virus de l'hépatite c
|
PL3290428T3
(pl)
|
2010-03-31 |
2022-02-07 |
Gilead Pharmasset Llc |
Tabletka zawierająca krystaliczny (S)-2-(((S)-(((2R,3R,4R,5R)-5-(2,4-diokso-3,4-dihydropirymidyn-1(2H)-ylo)-4-fluoro-3-hydroksy-4-metylotetrahydrofuran-2-ylo)metoksy)(fenoksy)fosforylo)amino)propanian izopropylu
|
JP6058528B2
(ja)
|
2010-03-31 |
2017-01-11 |
ギリアド ファーマセット エルエルシー |
ヌクレオシドホスホルアミデート
|
KR20130120481A
(ko)
|
2010-10-08 |
2013-11-04 |
노파르티스 아게 |
술파미드 ns3 억제제의 비타민 e 제제
|
JP6069215B2
(ja)
|
2010-11-30 |
2017-02-01 |
ギリアド ファーマセット エルエルシー |
化合物
|
TW201306841A
(zh)
|
2010-12-20 |
2013-02-16 |
Gilead Sciences Inc |
治療c型肝炎病毒(hcv)之方法
|
CA2752008A1
(en)
|
2011-09-13 |
2013-03-13 |
Universite De Montreal |
Combination therapy using ribavirin as elf4e inhibitor
|
MX354958B
(es)
|
2011-09-16 |
2018-03-27 |
Gilead Pharmasset Llc |
Metodos para el tratamiento de vhc.
|
US8889159B2
(en)
|
2011-11-29 |
2014-11-18 |
Gilead Pharmasset Llc |
Compositions and methods for treating hepatitis C virus
|
WO2014068265A1
(en)
|
2012-10-29 |
2014-05-08 |
Cipla Limited |
Antiviral phosphonate analogues and process for preparation thereof
|
US20140205566A1
(en)
|
2012-11-30 |
2014-07-24 |
Novartis Ag |
Cyclic nucleuoside derivatives and uses thereof
|
EP2950786B1
(en)
|
2013-01-31 |
2019-11-27 |
Gilead Pharmasset LLC |
Combination formulation of two antiviral compounds
|
PL3038601T3
(pl)
|
2013-08-27 |
2020-08-24 |
Gilead Pharmasset Llc |
Formulacja złożona dwóch związków przeciwwirusowych
|
WO2015197549A1
(en)
|
2014-06-23 |
2015-12-30 |
Sanovel Ilac Sanayi Ve Ticaret A.S. |
A novel pharmaceutical composition of sofosbuvir and ribavirin
|
EP2959891A1
(en)
|
2014-06-23 |
2015-12-30 |
Sanovel Ilac Sanayi ve Ticaret A.S. |
Modified release pharmaceutical compositions of sofosbuvir and ribavirin
|
EP2959901A1
(en)
|
2014-06-23 |
2015-12-30 |
Sanovel Ilac Sanayi ve Ticaret A.S. |
Pharmaceutical combinations of sofosbuvir and ribavirin
|
KR20190104438A
(ko)
|
2014-07-11 |
2019-09-09 |
길리애드 사이언시즈, 인코포레이티드 |
Hiv의 치료를 위한 톨-유사 수용체의 조정제
|
EA201790369A1
(ru)
|
2014-09-16 |
2017-10-31 |
Джилид Сайэнс, Инк. |
Твердые формы модулятора толл-подобного рецептора
|
TW201817714A
(zh)
|
2016-08-30 |
2018-05-16 |
英商葛蘭素史密斯克藍智慧財產權有限公司 |
抑制3c及3cl蛋白酶之化合物及其使用方法
|
CN110713464B
(zh)
*
|
2019-10-31 |
2023-03-31 |
重庆大学 |
一种芳基1,2,4-三氮唑核苷化合物及其制备方法和应用
|
WO2021209563A1
(en)
|
2020-04-16 |
2021-10-21 |
Som Innovation Biotech, S.A. |
Compounds for use in the treatment of viral infections by respiratory syndrome-related coronavirus
|